Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Neil L Berinstein, MD, Nancy M Pennell, BSc, Rashmi Weerasinghe, Matthew C. Cheung, MD SM, FRCPC, Eugenia Piliotis, MD FRCP, MD, Kevin R Imrie, MD, Mary-Anne Cussen, Rena Buckstein, MD, Zeina Ghorab, Ellen Miles, Marciano D. Reis, MD

Blood (2016) 128 (22): 1794.

https://doi.org/10.1182/blood.V128.22.1794.1794

Published: 2016

Journal Articles

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Tony Reiman, MD, Kerry J. Savage, MD MSc, Michael Crump, MD, Matthew Cheung, MD, David A. MacDonald, MD, Rena Buckstein, MD, Stephen Couban, MD, Eugenia Piliotis, MD, Kevin R Imrie, MD, David Spaner, MD PhD, Sudeep Shivakumar, MD, John Kuruvilla, MD, Diego Villa, Lois E. Shepherd, MD, Tanya Skamene, MD, Chad Winch, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 4162.

https://doi.org/10.1182/blood.V128.22.4162.4162

Published: 2016

Journal Articles

Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature

Anca Prica, MD, Ariella Pratzer, Matthew C Cheung, MD, Kim Thompson, Eugenia Piliotis, MD, Neil L Berinstein, MD, Kevin R. Imrie, MD, Rahim Pradhan, Anju Vyas, David Good, MD, Liying Zhang, PhD, Rena Buckstein, MD

Blood (2013) 122 (21): 5093.

https://doi.org/10.1182/blood.V122.21.5093.5093

Published: 2013

Journal Articles

Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab

Neil L Berinstein, MD, FRCPC, Nancy M Pennell, B Sc, Mary-Anne Cussen, RN, BScN, CCRP, Kevin R Imrie, MD, Eugenia Piliotis, MD, FRCPC, Rena Buckstein, MD, Zeina Ghorab, MD, Ellen Anne Miles, MSc, Alden E. Chesney, MD, Matthew Cheung, MD

Blood (2012) 120 (21): 3681.

https://doi.org/10.1182/blood.V120.21.3681.3681

Published: 2012

Journal Articles

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Blood (2012) 120 (21): 745.

https://doi.org/10.1182/blood.V120.21.745.745

Published: 2012

Journal Articles

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Nancy M Pennell, B Sc, Matthew Cheung, MD, MS, FRCP, Lisa K Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Kevin R Imrie, MD, Rena Buckstein, MD, FRCPC, Cindy Davidson, RN, Mary-Anne Cussen, RN, BScN, CCRP, Zeina Ghorab, MD, Alden Chesney, MD, FRCPC, Neil L Berinstein, MD, FRCPC

Blood (2011) 118 (21): 2701.

https://doi.org/10.1182/blood.V118.21.2701.2701

Published: 2011

Journal Articles

Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis

Lee Mozessohn, MD, Matthew Cheung, MD, FRCPC, Michael Crump, MD, FRCPC, Rena Buckstein, MD, FRCPC, Neil L Berinstein, MD, FRCPC, Kevin R. Imrie, MD, FRCPC, John Kuruvilla, MD, FRCPC, Eugenia Piliotis, MD, FRCPC, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4981.

https://doi.org/10.1182/blood.V118.21.4981.4981

Published: 2011

Journal Articles

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Sita Bhella, MD, Neil L Berinstein, MD, FRCPC, Nancy Pennell, BSc, Matthew Cheung, MD, FRCPC, Kevin R. Imrie, MD, FRCPC, Violet Miliken, Marciano D. Reis, MD, FRCPC, Alden Chesney, MD, FRCPC, David Good, MD, FRCPC, Lisa Hicks, MD, MSc, FRCPC, Eugenia Piliotis, MD, FRCPC, Michael Crump, MD, FRCPC, Rena Buckstein, MD, FRCPC

Blood (2010) 116 (21): 1357.

https://doi.org/10.1182/blood.V116.21.1357.1357

Published: 2010

Journal Articles

Trends in the Incidence of HIV-Related Hematologic Malignancies in the Era of Combination Antiretroviral Therapy and Predictors of HIV-Related Non-Hodgkin's Lymphoma Development and Survival.

Linda R Taggart, MD, Pierre K Isogai, B.Sc, Nancy Risebrough, B.A., Nicole Mittmann, MSc, PhD, Anita R Rachlis, MD, Kevin R Imrie, MD, Matthew C Cheung, MD

Blood (2009) 114 (22): 1916.

https://doi.org/10.1182/blood.V114.22.1916.1916

Published: 2009

Journal Articles

Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group.

Laurie H. Sehn, MD, MPH, David A Macdonald, MD, Sheldon H. Rubin, MD, Guy Cantin, MD, Morel Rubinger, MD, Bernard Lemieux, MD, Sanraj Basi, MD, Kevin R Imrie, MD, Randy D. Gascoyne, Bingshu Chen, PhD, Marina Djurfeldt, MSc, Lois Shepherd, MD, Stephen Couban, MD, Michael Crump, MD

Blood (2009) 114 (22): 407.

https://doi.org/10.1182/blood.V114.22.407.407

Published: 2009

Journal Articles

Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies

Nancy Pennell, Matthew Cheung, MD SM, FRCP, Lisa K Hicks, MD, MSc, Rena Buckstein, MD, FRCPC, Kevin R Imrie, MD, Eugenia Piliotis, MD, David Spaner, Zeina Ghorab, Marciano D. Reis, MD, Violet Milliken, Angela Boudreau, Neil Berinstein, MD

Blood (2008) 112 (11): 4351.

https://doi.org/10.1182/blood.V112.11.4351.4351

Published: 2008

Journal Articles

Sezary Syndrome and Combination Immunomodulatory Therapy: Improving Clinical Outcomes

Eugenia Piliotis, MD, Panayiota Govas, Kevin R Imrie, MD, Matthew C Cheung, MD, Neil Shear, Scott Walsh, MD, FRCPC, Cathy Fairlie, RN, David Barth, MD, FRCPC

Blood (2008) 112 (11): 4957.

https://doi.org/10.1182/blood.V112.11.4957.4957

Published: 2008

Journal Articles

Tolerability and Efficacy of Bortezomib Added to CVP-R for Previously Untreated Advanced Stage Follicular Lymphoma: Interim Analysis of a Phase II Study by the NCIC Clinical Trials Group.

Laurie H Sehn, MD, MPH, David A Macdonald, MD, Sheldon H. Rubin, MD, Morel Rubinger, MD, FRCPC, Kevin R Imrie, MD, Judy-Anne W Chapman, PhD, Marina Djurfeldt, Lois Shepherd, MD, Stephen Couban, MD, Michael Crump, MD

Blood (2008) 112 (11): 1576.

https://doi.org/10.1182/blood.V112.11.1576.1576

Published: 2008

Journal Articles

Prolonged Clinical and Molecular Remissions Following High-Dose Therapy/Autologous Stem Cell Transplantation (HDT/ASCT) and Rituximab and Interferon-alpha Maintenance for Relapsed High-Risk Follicular Lymphoma.

Matthew C. Cheung, MD, Neil L. Berinstein, MD, Nancy Pennell, BSc, Lisa K. Hicks, MD, Kevin R. Imrie, MD, Eugenia Piliotis, MD, Violet Milliken, BSc, Marciano Reis, MD, Rena Buckstein, MD

Blood (2007) 110 (11): 1902.

https://doi.org/10.1182/blood.V110.11.1902.1902

Published: 2007

Journal Articles

Discrimination of Health States in Follicular Lymphoma with Utilities Derived from the EuroQOL EQ5D Instrument.

Jessica D. Friedlich, Matthew C. Cheung, MD, Kevin R. Imrie, MD, Brigette Hales, MSc, Nicole Mittmann, PhD, Rena Buckstein, MD

Blood (2006) 108 (11): 3329.

https://doi.org/10.1182/blood.V108.11.3329.3329

Published: 2006

Journal Articles

The Potential for Lost Productivity and Daily Activity Impairment in Patients with Follicular (FL) and Other Indolent Non-Hodgkin’s Lymphoma (NHL).

Matthew C. Cheung, MD, Kevin R. Imrie, MD, Jessica Friedlich, Rena Buckstein, MD, Lisa K. Hicks, MD, Yael Zaretsky, MD, Brigette Hales, MSc, Eugenia Piliotis, MD, Nicole Mittmann, PhD

Blood (2006) 108 (11): 344.

https://doi.org/10.1182/blood.V108.11.344.344

Published: 2006

Journal Articles

Physician Adherence to Local Treatment Policies and American Society of Hematology (ASH) Quality Metrics in Chronic Lymphocytic Leukemia (CLL) Management.

Jessica D. Friedlich, Matthew C. Cheung, MD, Rena Buckstein, MD, Kevin R. Imrie, MD

Blood (2006) 108 (11): 78.

https://doi.org/10.1182/blood.V108.11.78.78

Published: 2006

NARROW

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature

Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

First Evidence for High Incidence of Complete and Sustained Molecular Remissions and Maintenance of Immune Responses in Patients Receiving Consolidation with Y90 Ibritumomab Tiuxetan ( 90 Y-RIT) Post R-CHOP for Newly Diagnosed Advanced Stage High and Intermediate Risk Follicular Lymphoma

Rituximab Resistant Follicular Lymphoma: Predictors of Rituximab Resistance, Incidence of Transformation and Prognosis

The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Trends in the Incidence of HIV-Related Hematologic Malignancies in the Era of Combination Antiretroviral Therapy and Predictors of HIV-Related Non-Hodgkin's Lymphoma Development and Survival.

Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group.

Hypogammaglobulinemia Following Rituximab and High-Dose Therapy and Autologous Stem-Cell Transplant: Incidence and Predictors of Prolonged Immunoglobulin Deficiencies

Sezary Syndrome and Combination Immunomodulatory Therapy: Improving Clinical Outcomes

Tolerability and Efficacy of Bortezomib Added to CVP-R for Previously Untreated Advanced Stage Follicular Lymphoma: Interim Analysis of a Phase II Study by the NCIC Clinical Trials Group.

Prolonged Clinical and Molecular Remissions Following High-Dose Therapy/Autologous Stem Cell Transplantation (HDT/ASCT) and Rituximab and Interferon-alpha Maintenance for Relapsed High-Risk Follicular Lymphoma.

Discrimination of Health States in Follicular Lymphoma with Utilities Derived from the EuroQOL EQ5D Instrument.

The Potential for Lost Productivity and Daily Activity Impairment in Patients with Follicular (FL) and Other Indolent Non-Hodgkin’s Lymphoma (NHL).

Physician Adherence to Local Treatment Policies and American Society of Hematology (ASH) Quality Metrics in Chronic Lymphocytic Leukemia (CLL) Management.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only